Swissmedic approves COVID-19 vaccine from Pfizer/BioNTech for children aged 5 to 11 years
10 December 2021 – Swissmedic has examined all the data submitted with the application for an indication extension for the COVID-19 vaccine from Pfizer/BioNTech (Comirnaty®). The clinical trial results show that the vaccine is safe and effective in this age group. During its meeting held on 7 December 2021, the independent Human Medicines Expert Committee (HMEC) backed the agency's decision. The COVID-19 vaccine for children is given in two doses of 10 micrograms three weeks apart. This is one-third of the dose given to adolescents and adults. It will thus be possible for children aged 5 years and older to be vaccinated against the new coronavirus (SARS-CoV-2) in accordance with the federal government’s updated vaccination recommendations.
For more information, see here.